Escugen Biotechnology | ApexOnco - Clinical Trials news and analysis

x

“It's very intuitive and always up-to-date”

Monika Vogelmann

Head of Market Insights Oncology Europe

Daiichi Sankyo

Click here for more information

Conferences Trial results

22 July 2024

ESMO 2024 preview – conjugates in the spotlight

Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.

Conferences Trial results

10 December 2023

ASH 2023 – lupus target could work in lymphoma too

Subscribe to Escugen Biotechnology